The latter half of the 20th century presented a new array of challenges and opportunities for both Nordisk and Novo, culminating in the most significant transformation of their history. The advent of biotechnology, particularly recombinant DNA technology in the 1970s and 1980s, revolutionized pharmaceutical development. This scientific leap, pioneered by researchers like Herbert Boyer and Stanley Cohen, and commercialized by companies such as Genentech, made it possible to produce human insulin identical to that produced by the body. This offered a cleaner, more consistent, and ultimately safer alternative to animal-sourced insulin, which, despite decades of refinement, could sometimes cause allergic reactions due to subtle amino acid differences (porcine insulin varied by one amino acid, bovine by three) and often required extensive purification. The shift to biotechnologically produced human insulin also alleviated concerns about the long-term availability of animal pancreases, which were finite resources. This technological paradigm shift necessitated substantial investment in new research capabilities, sophisticated fermentation processes, and specialized production infrastructure.
Both companies independently recognized the imperative to adapt to this biotechnological revolution. Novo Terapeutisk Laboratorium was particularly swift in embracing the new biotechnology, leveraging its existing expertise in industrial fermentation from its enzyme division. In 1982, Novo became one of the first companies globally to successfully produce recombinant human insulin, marketed as Actrapid Human. This pivotal achievement not only demonstrated Novo’s technological prowess but also positioned it as a forward-thinking innovator in the evolving pharmaceutical landscape. Crucially, this placed Novo in direct competition with Eli Lilly and Company, which also launched its recombinant human insulin, Humulin, in the same year, sparking an immediate global rivalry for market leadership in this new era of diabetes treatment. Nordisk, while also pursuing similar research in recombinant human insulin, continued to strengthen its portfolio of animal insulins, focusing on advanced formulations such as improved NPH (isophane) and Lente insulins that offered more consistent and prolonged action, alongside enhancing purification techniques to minimize side effects.
However, the intensifying global competition from major pharmaceutical players, notably Eli Lilly with its significant resources and established global distribution network, underscored the need for consolidation. The two Danish insulin pioneers, Nordisk and Novo, despite their shared national heritage and common dedication to diabetes care, had operated as distinct and often competing entities for over six decades. Internal documents and market analyses indicated that a unified entity would be better equipped to compete on a global scale, share extensive research & development costs – particularly vital for the capital-intensive biotechnology sector – and leverage combined market strengths to negotiate with increasingly powerful healthcare payers and providers. This realization, driven by the strategic imperative to create a dominant global player capable of challenging rivals like Eli Lilly, ultimately led to negotiations for a merger.
In 1989, Nordisk Gentofte A/S (the successor to Nordisk Insulinlaboratorium) and Novo Industri A/S (the successor to Novo Terapeutisk Laboratorium) officially merged to form Novo Nordisk A/S. This strategic consolidation was a monumental pivot, transforming the competitive landscape of diabetes care by creating a formidable new entity. The merger combined Nordisk's deep research heritage, particularly in insulin pharmacology and long-acting insulin formulations, with Novo's industrial scale, advanced biotech capabilities, and strong global commercial presence, including its significant industrial enzymes division. Pre-merger, Novo Industri was generally a larger and more diversified entity, while Nordisk Gentofte possessed a highly specialized and respected diabetes legacy. The integration process, while complex due to merging two distinct corporate cultures and operational structures, aimed to synergize their respective strengths and create a more efficient, innovation-driven organization with a projected global market share that instantly positioned it among the top diabetes care providers worldwide.
Post-merger, Novo Nordisk aggressively expanded its R&D capabilities, focusing not only on recombinant human insulin but also on developing next-generation insulin analogues. These new insulins, such as NovoRapid (insulin aspart), a rapid-acting analogue, and Levemir (insulin detemir), a long-acting basal analogue, were engineered for even better patient control and convenience by more closely mimicking the body's natural insulin release patterns. This period also saw the introduction and widespread adoption of advanced insulin delivery systems, such as the widely acclaimed NovoPen and FlexPen, which revolutionized how patients administered their medication, moving away from traditional vials and syringes. These user-friendly pens simplified dosing, improved accuracy, reduced the psychological barrier associated with injections, and significantly enhanced patient adherence, thus improving treatment outcomes and solidifying Novo Nordisk's reputation as a patient-centric company focused on holistic diabetes management.
Challenges during this transformative period included intense regulatory scrutiny for novel biological products across major markets like the U.S. (FDA) and Europe (EMA), global pricing pressures from healthcare systems seeking to control costs, and the continuous need to justify the value of innovative, often more expensive, new treatments. The company also navigated internal issues related to integrating two distinct corporate cultures, different R&D pipelines, and operational structures, requiring significant change management efforts. Additionally, in a crucial strategic decision in 2000, Novo Nordisk opted to spin off its industrial enzymes and biopharmaceuticals division into a separate, publicly traded company, Novozymes A/S. This move allowed Novo Nordisk to sharpen its focus exclusively on pharmaceutical products, particularly in its core therapeutic areas of diabetes, hemophilia, and growth hormone disorders, while allowing Novozymes to pursue its distinct growth strategy in industrial biotechnology. This separation, which unlocked value for shareholders by allowing each entity to be assessed on its specific business model, created a pure-play pharmaceutical company.
This strategic restructuring proved prescient, enabling Novo Nordisk to concentrate resources on its pharmaceutical pipeline with unparalleled clarity. The company began exploring beyond insulin, particularly into related metabolic disorders, leveraging its deep understanding of metabolic pathways and its existing patient base. This focus would eventually lead to the development of its groundbreaking GLP-1 receptor agonists, starting with Victoza (liraglutide) in 2009. The launch of Victoza marked a significant expansion of its diabetes portfolio, offering new therapeutic avenues beyond traditional insulin replacement by influencing glucose-dependent insulin secretion, glucagon suppression, and appetite regulation. This class of drugs represented a paradigm shift in diabetes management, providing benefits like weight loss in addition to glycemic control. Victoza's success laid the groundwork for its future diversification into other serious chronic diseases like obesity, building upon its existing strong presence in hemophilia and growth hormone disorders, cementing its status as a highly specialized and increasingly diversified pharmaceutical giant.